Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
No, all RGCC tests are currently ordered by registered practitioners. Our Customer Relations team is happy to provide you with practitioners in your area. Please contact us.
Our tests can be utilized for all types of hematological and solid cancers, at various stages, outside of brain tumors because of the blood brain barrier not allowing the cells into general circulation.
Please see our published research articles, here: https://rgcc-international.com/published-articles/
To order an RGCC test or therapy, the doctor must be registered with RGCC. To become an RGCC Registered Practitioner, please have your doctor visit https://myrgcc.com/contact-us/ and someone from our RGCC College team will contact them with next steps.
All test results are posted to your RGCC Practitioner's Portal approximately 2 weeks from the time the blood arrives at the lab (and 3-4 weeks for ArrayCGH RGCC tests). Once your results are available, your practitioner will reach out to you to review and interpret your results.
All our registered practitioners are trained to guide you through the testing options and will make recommendations that are right for you.
The power of our monitoring tests is they give you a measure of whether a treatment option is working or not so you can change course if needed. Along with the Onconomics panels which provide information about personalized treatment options, you have information on options that may be more effective for you.
Each patient is unique. How often you should see your practitioner must be decided in consultation with them after they have reviewed your case. Although this timing may vary based on factors such as treatment options, within our process, monitoring is recommended every 3 months with active cancer to monitor effectiveness of treatments, and every 6-12 months in remission to monitor for early signs of recurrence as part of your Recurrence Prevention Program.
Even when you receive the “all clear” from your Oncologist, there may be CSCs (Circulating Stem Cell-like Cells) also known as TICs (Tumor Initiating Cells) still active and in circulation but at a level below the sensitivity of standard-of-care monitoring tests, such as imaging and physiological cancer marker testing.
This means active cancer cells may be present, but they cannot be detected via traditional means until the cancer has grown big enough to be detected again. This leaves you vulnerable and without treatment because in the standard-of-care model, if you can’t see it, you can’t treat it, enabling the cancer to come back.
TIC monitoring with our Oncotrace and Oncotrail RGCC allows you to monitor these cells on a microscopic level allowing you to continue care until these cells are no longer active or if in remission, allowing you to see new activity as soon as it starts.
Cancer is often more aggressive when there is a recurrence. This highlights the importance of having a Recurrence Prevention Program once the cancer has gone into remission or as part of your post-treatment aftercare.
Standard-of-care monitoring tests are not sensitive enough to detect early-stage recurrence activity. This allows cancer to take hold before it is detected, making it harder to treat. If you can’t see it, you can’t treat it.
At RGCC, our Oncocount, Oncotrace, and Oncotrail RGCC monitoring tests detect the presence of cancer cells on a microscopic level, allowing for the earliest detection and treatment of recurrence allowing for a proactive, rather than reactive approach to care.
No. Cancer is not contagious and cannot be passed from one person to another.
Our team at RGCC North America is happy to provide you with a list of registered practitioners. Simply fill out the contact form and our team will begin building your personalized referral list.
Blood draw kits can only be ordered by our registered practitioner. Simply fill out the contact form and our team will begin building your personalized referral list.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
